STUDY TO DETERMINE ADEQUATE MARGINS IN RADIOTHERAPY PLANNING FOR ESOPHAGEAL CARCINOMA BY DETAILING PATTERNS OF RECURRENCE AFTER DEFINITIVE CHEMORADIOTHERAPY

被引:117
|
作者
Button, Michael R. [4 ]
Morgan, Carys A. [1 ]
Croydon, Elizabeth S. [2 ]
Roberts, S. Ashley [3 ]
Crosby, Thomas D. L. [4 ]
机构
[1] Bristol Oncol Ctr, Dept Clin Oncol, Bristol, Avon, England
[2] Chase Farm Hosp, Enfield, Middx, England
[3] Univ Wales Hosp, Dept Radiol, Cardiff CF4 4XW, S Glam, Wales
[4] Velindre Oncol Ctr, Dept Clin Oncol, Cardiff, S Glam, Wales
关键词
Esophageal cancer; Chemoradiotherapy; Relapse patterns; Radiotherapy margins; POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; NEOADJUVANT CHEMORADIOTHERAPY; CHEMOTHERAPY; CANCER; CHEMORADIATION; SURGERY; RADIATION; CETUXIMAB; TRIAL;
D O I
10.1016/j.ijrobp.2008.04.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To ascertain the adequacy of radiotherapy (RT) margins by studying the relapse patterns after definitive chemoradiotherapy for carcinoma of the esophagus. Methods and Materials: We performed a retrospective study assessing the first site of disease relapse after definitive chemoradiotherapy that included four 3-weekly cycles of cisplatin and continuous infusion 5-fluorouracil, with conformal RT (50 Gy in 25 fractions) concurrent with Cycles 3 and 4. The RT planning target volume was the endoscopic ultrasonography/computed tomography-defined gross tumor volume with 1.5-cm lateral and 3-cm superoinferior margins. Results: A total of 145 patients were included. Their average age was 65.4 years, 45% had adenocarcinoma, 61% bad lower third esophageal tumors, and 75% had Stage III-IVA disease. After RT, of 142 patients, 85 (60%) had evidence of relapse at a median follow-up of 18 months. The relapse was local (within the RT field) in 55; distant (metastatic) in 13, and a combination of local and distant in 14. The local relapse rates were not influenced by tumor stage, lymph node status, or disease length. Three patients developed a relapse in regions adjacent to the RT fields; however, it is unlikely that larger field margins would have been clinically acceptable or effective in these cases. The median overall survival was 15 months. Conclusion: The gross tumor volume-planning target volume margins in this study appeared adequate. Future efforts to improve outcomes using definitive chemoradiotherapy should be directed toward reducing the high rates of in-field and distant relapses. (C) 2009 Elsevier Inc.
引用
收藏
页码:818 / 823
页数:6
相关论文
共 50 条
  • [21] Endoscopic resection for local residual or recurrent cancer after definitive chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma
    Tani, Yasuhiro
    Ishihara, Ryu
    Matsuura, Noriko
    Okubo, Yuki
    Kawakami, Yushi
    Sakurai, Hirohisa
    Nakamura, Takahiko
    Matsueda, Katsunori
    Miyake, Muneaki
    Shichijo, Satoki
    Maekawa, Akira
    Kanesaka, Takashi
    Yamamoto, Sachiko
    Takeuchi, Yoji
    Higashino, Koji
    Uedo, Noriya
    Michida, Tomoki
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [22] Endoscopic resection for local residual or recurrent cancer after definitive chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma
    Yasuhiro Tani
    Ryu Ishihara
    Noriko Matsuura
    Yuki Okubo
    Yushi Kawakami
    Hirohisa Sakurai
    Takahiko Nakamura
    Katsunori Matsueda
    Muneaki Miyake
    Satoki Shichijo
    Akira Maekawa
    Takashi Kanesaka
    Sachiko Yamamoto
    Yoji Takeuchi
    Koji Higashino
    Noriya Uedo
    Tomoki Michida
    Scientific Reports, 13
  • [23] FACTORS PREDICTIVE OF TUMOR RECURRENCE AND SURVIVAL AFTER INITIAL COMPLETE RESPONSE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA TO DEFINITIVE CHEMORADIOTHERAPY
    Ishihara, Ryu
    Yamamoto, Sachiko
    Iishi, Hiroyasu
    Takeuchi, Yoji
    Sugimoto, Naotoshi
    Higashino, Koji
    Uedo, Noriya
    Tatsuta, Masaharu
    Yano, Masahiko
    Imai, Atsushi
    Nishiyama, Kinji
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (01): : 123 - 129
  • [24] Minimally invasive hybrid surgery: A salvage tumor enucleation for local recurrence of thoracic esophageal carcinoma after definitive chemoradiotherapy
    Kanamori, Jun
    Abe, Seiichiro
    Kurita, Daisuke
    Ishiyama, Koshiro
    Hirano, Yuki
    Oguma, Junya
    Oda, Ichiro
    Saito, Yutaka
    Daiko, Hiroyuki
    ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 2021, 14 (01) : 77 - 80
  • [25] Late toxicity after definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma
    Kumekawa, Yosuke
    Kaneko, Kazuhiro
    Ito, Hiroaki
    Kurahashi, Toshinori
    Yamamoto, Taikan
    Kuwahara, Meiko
    Kubota, Yotaro
    Muramoto, Takashi
    Imawari, Michio
    GASTROENTEROLOGY, 2006, 130 (04) : A415 - A415
  • [26] Prognostic Factors for Patients with Esophagus Carcinoma after primary definitive Radiotherapy or Chemoradiotherapy
    Haefner, M. F.
    Krug, D.
    Lang, K.
    Koerber, S. A.
    Uhlmann, L.
    Debus, J.
    Sterzing, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 106 - 106
  • [27] CARCINOMA OF ESOPHAGUS - SITES OF RECURRENCE AND PALLIATIVE BENEFITS AFTER DEFINITIVE RADIOTHERAPY
    ELKON, D
    LEE, MS
    HENDRICKSON, FR
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1978, 4 (7-8): : 615 - 620
  • [28] Metalic stent implantation for local recurrence after chemoradiotherapy of esophageal carcinoma
    Kaneko, K
    Kurahashi, T
    Konishi, K
    Ito, H
    Mitamura, K
    GASTROENTEROLOGY, 1999, 116 (04) : A432 - A432
  • [29] Survival Study of Adjuvant Radiotherapy and Chemotherapy after Definitive Surgery of Locally Advanced Esophageal Carcinoma
    Zhu, S.
    Su, J.
    Li, J.
    Shen, W.
    Liu, Z.
    Song, C.
    Li, Y.
    Wang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S323 - S323
  • [30] Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
    Zhao, Fangdong
    Wang, Qifeng
    Han, Weiming
    Maitudi, Wubulaishan
    Cao, Fuliang
    Zhang, Tian
    Chen, Xi
    Dong, Jie
    Gong, Lei
    Shang, Xiaobin
    Jiang, Hongjing
    Zhang, Wencheng
    Pang, Qingsong
    Xiao, Zefen
    Wang, Ping
    Tang, Peng
    CANCER MEDICINE, 2025, 14 (04):